Published in Pharmacotherapy on August 01, 2011
The role of myeloid cells in cancer therapies. Nat Rev Cancer (2016) 0.92
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther (2013) 0.90
Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate. Front Immunol (2015) 0.82
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs (2013) 0.80
Molecular mimics of the tumour antigen MUC1. PLoS One (2012) 0.80
Immune response to sipuleucel-T in prostate cancer. Cancers (Basel) (2012) 0.79
Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res (2014) 0.78
Cancer prevention: state of the art and future prospects. J Prev Med Hyg (2015) 0.77
Mechanism and Function of Angiogenin in Prostate Cancer. (2015) 0.75
The role of chemotherapy and new targeted agents in the management of primary prostate cancer. J Clin Urol (2016) 0.75
Personalized medicine could transform healthcare. Biomed Rep (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol (1989) 7.69
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
T cell anergy. Annu Rev Immunol (2001) 7.15
Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 6.45
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
A new member of the immunoglobulin superfamily--CTLA-4. Nature (1987) 5.10
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Coley's toxins in perspective. Nature (1992) 3.40
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
New therapies for castration-resistant prostate cancer. N Engl J Med (2010) 2.37
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
The immune system. First of two parts. N Engl J Med (2000) 2.05
When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst (2010) 1.95
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate (2004) 1.50
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res (2005) 1.48
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 1.48
The immune system. Second of two parts. N Engl J Med (2000) 1.40
Regulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cells. J Immunol (2000) 1.39
Peripherally induced Treg: mode, stability, and role in specific tolerance. J Clin Immunol (2008) 1.14
Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine (2007) 1.13
Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther (2001) 1.10
Regulatory T-cell development: is Foxp3 the decider? Nat Med (2007) 1.10
Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst (2010) 1.02
HLA class I antigen loss, tumor immune escape and immune selection. Vaccine (2002) 0.99
Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol (2009) 0.96
Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control (2003) 0.93
Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ (2010) 0.92
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther (2009) 0.89
Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther (2002) 0.88
Prostate cancer: advances in immunotherapy. BioDrugs (2003) 0.85
Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines (2010) 0.84
BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas. Curr Opin Mol Ther (2008) 0.78
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. Cancer Discov (2011) 1.52
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int (2010) 1.40
Harnessing the power of the immune system to target cancer. Annu Rev Med (2012) 1.33
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med (2014) 1.18
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun (2008) 0.93
Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol (2010) 0.86
Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines (2010) 0.84
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res (2013) 0.82
Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol (2012) 0.81
Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol (2014) 0.81
Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol (2011) 0.78
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol (2013) 0.77
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell (2015) 0.76
Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature (2017) 0.75